TELA Bio, Inc., a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient’s own anatomy, has announced the pricing of its previously announced underwritten public offering of 4,750,000 shares of its common stock at a price to the public of US$9.50 per share, for gross proceeds of US$45.125 million, before deducting underwriting discounts and commissions and other estimated offering expenses. In addition, TELA has granted the underwriters a 30-day option to purchase up to an additional 712,500 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by TELA. The offering is expected to close on or about April 21, 2023, subject to the satisfaction of customary closing conditions.,

Latham & Watkins LLP represents the underwriters in the offering with a New York capital markets team led by partners Marc Jaffe and Nathan Ajiashvili, with associates Egzon Sulejmani, and Yulong Li.